CD4 and primary cutaneous T-cell non-Hodgkin lymphoma: Consistent with our data, the findings reported for Sézary patients (14) also support the distinction of reactive (IFNγ+) from potentially malignant (TOX+ IL-4+) CD4+ T cells in CTCL patients.